{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:26:40Z","timestamp":1791163600035,"version":"4.1.0"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"20","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fms-like tyrosine kinase 3 (FLT3) is highly expressed in acute lymphoblastic leukemia with the mixed-lineage leukemia (MLL) gene rearrangement refractory to chemotherapy. We examined the biological effect of FLT3-ligand (FL) on 18 B-precursor leukemic cell lines with variable karyotypic abnormalities, and found that nine of nine MLL-rearranged cell lines with wild-type FLT3, in contrast to other leukemic cell lines, are significantly inhibited in their proliferation in a dose-dependent manner by FL. This inhibition was due to induction of the G0-G1 arrest. A marked up-regulation of p27 by suppression of its protein degradation and an abrogation of constitutive signal transducers and activators of transcription 5 phosphorylation were revealed in arrested leukemia cells after FL stimulation. Importantly, FL treatment rendered not only cell lines but also primary leukemia cells with MLL rearrangement resistant to chemotherapeutic agents. MLL-rearranged leukemia cells adhering to the bone marrow stromal cell line, which expresses FL as the membrane-bound form, were induced to quiescent state resistant to chemotherapeutic agents, but their chemosensitivity was significantly restored in the presence of neutralizing anti-FL antibody. The FL\/FLT3 interaction between leukemia cells and bone marrow stromal cells expressing FL at high levels should contribute, at least in part, to persistent minimal-residual disease of MLL-rearranged leukemia in bone marrow. [Cancer Res 2007;67(20):9852\u201361]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-0105","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T17:39:01Z","timestamp":1192642741000},"page":"9852-9861","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Fms-like Tyrosine Kinase 3 Ligand Stimulation Induces\n                    <i>MLL<\/i>\n                    -Rearranged Leukemia Cells into Quiescence Resistant to Antileukemic Agents"],"prefix":"10.1158","volume":"67","author":[{"given":"Yoshiyuki","family":"Furuichi","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Goi","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nemoto","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Hirose","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Honna","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Kuroda","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Hayashi","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, Gunma Children's Medical Center, Gumma, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harigaya","sequence":"additional","affiliation":[{"name":"3Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Sugita","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"2022061623192193800_B1","unstructured":"Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR\/CSF1R family. Oncogene\u20081991; 6: 1641\u201350."},{"key":"2022061623192193800_B2","doi-asserted-by":"crossref","unstructured":"Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell\u20081991; 65: 1143\u201352.","DOI":"10.1016\/0092-8674(91)90010-V"},{"key":"2022061623192193800_B3","doi-asserted-by":"crossref","unstructured":"Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3\/FLK2 Gene: cDNA cloning and expression in hematopoietic cells. Blood\u20081993; 82: 1110\u20139.","DOI":"10.1182\/blood.V82.4.1110.1110"},{"key":"2022061623192193800_B4","doi-asserted-by":"crossref","unstructured":"Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci U S A\u20081994; 91: 459\u201363.","DOI":"10.1073\/pnas.91.2.459"},{"key":"2022061623192193800_B5","unstructured":"Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates\/costimulates the growth of myeloid stem\/progenitor cells. Exp Hematol\u20081995; 23: 1121\u20139."},{"key":"2022061623192193800_B6","doi-asserted-by":"crossref","unstructured":"Piacibello W, Fubini L, Sanavio F, et al. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood\u20081995; 86: 4105\u201314.","DOI":"10.1182\/blood.V86.11.4105.bloodjournal86114105"},{"key":"2022061623192193800_B7","doi-asserted-by":"crossref","unstructured":"Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias. Blood\u20081996; 87: 1089\u201396.","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089"},{"key":"2022061623192193800_B8","unstructured":"Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia\u20081996; 10: 588\u201399."},{"key":"2022061623192193800_B9","unstructured":"McKenna HJ, Smith FO, Brasel K, et al. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children. Exp Hematol\u20081996; 24: 378\u201385."},{"key":"2022061623192193800_B10","unstructured":"Nakao M, Yokota S, lwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia\u20081996; 10: 1911\u20138."},{"key":"2022061623192193800_B11","doi-asserted-by":"crossref","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol\u20082001; 113: 983\u20138.","DOI":"10.1046\/j.1365-2141.2001.02850.x"},{"key":"2022061623192193800_B12","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood\u20082001; 97: 2434\u20139.","DOI":"10.1182\/blood.V97.8.2434"},{"key":"2022061623192193800_B13","doi-asserted-by":"crossref","unstructured":"Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood\u20082001; 98: 1752\u20139.","DOI":"10.1182\/blood.V98.6.1752"},{"key":"2022061623192193800_B14","doi-asserted-by":"crossref","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood\u20082002; 100: 1532\u201342.","DOI":"10.1182\/blood-2002-02-0492"},{"key":"2022061623192193800_B15","doi-asserted-by":"crossref","unstructured":"Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol\u20081999; 105: 155\u201362.","DOI":"10.1111\/j.1365-2141.1999.01284.x"},{"key":"2022061623192193800_B16","doi-asserted-by":"crossref","unstructured":"Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood\u20082003; 102: 2387\u201394.","DOI":"10.1182\/blood-2002-12-3627"},{"key":"2022061623192193800_B17","doi-asserted-by":"crossref","unstructured":"Pui CH, Behm FG, Downing JR, et al. 11q23\/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol\u20081994; 12: 909\u201315.","DOI":"10.1200\/JCO.1994.12.5.909"},{"key":"2022061623192193800_B18","unstructured":"Taki T, Ida K, Bessho F, et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia\u20081996; 10: 1303\u20137."},{"key":"2022061623192193800_B19","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet\u20082002; 30: 41\u20137.","DOI":"10.1038\/ng765"},{"key":"2022061623192193800_B20","doi-asserted-by":"crossref","unstructured":"Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood\u20082004; 103: 1085\u20138.","DOI":"10.1182\/blood-2003-02-0418"},{"key":"2022061623192193800_B21","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification. Cancer Cell\u20082003; 3: 173\u201383.","DOI":"10.1016\/S1535-6108(03)00003-5"},{"key":"2022061623192193800_B22","doi-asserted-by":"crossref","unstructured":"Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood\u20082005; 105: 812\u201320.","DOI":"10.1182\/blood-2004-06-2498"},{"key":"2022061623192193800_B23","doi-asserted-by":"crossref","unstructured":"Nakamura M, Sugita K, Inukai T, et al. p16\/MTS1\/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia\u20081999; 13: 884\u201390.","DOI":"10.1038\/sj.leu.2401437"},{"key":"2022061623192193800_B24","doi-asserted-by":"crossref","unstructured":"Inukai T, Sugita K, Iijima K, et al. Leukemic cells with 11p23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia\u20081998; 12: 382\u20139.","DOI":"10.1038\/sj.leu.2400951"},{"key":"2022061623192193800_B25","doi-asserted-by":"crossref","unstructured":"Harigaya K, Handa H. Generation of functional clonal cell lines from human bone marrow stroma. Proc Natl Acad Sci U S A\u20081985; 82: 3477\u201380.","DOI":"10.1073\/pnas.82.10.3477"},{"key":"2022061623192193800_B26","doi-asserted-by":"crossref","unstructured":"Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3\/Flt3 cells. J Leukoc Biol\u20081999; 65: 372\u201380.","DOI":"10.1002\/jlb.65.3.372"},{"key":"2022061623192193800_B27","doi-asserted-by":"crossref","unstructured":"Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med\u20082000; 192: 719\u201328.","DOI":"10.1084\/jem.192.5.719"},{"key":"2022061623192193800_B28","doi-asserted-by":"crossref","unstructured":"Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer\u20082003; 3: 650\u201365.","DOI":"10.1038\/nrc1169"},{"key":"2022061623192193800_B29","unstructured":"Lisovsky M, Braun SE, Ge Y, et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia\u20081996; 10: 1012\u20138."},{"key":"2022061623192193800_B30","doi-asserted-by":"crossref","unstructured":"Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet\u20082002; 359: 1909\u201315.","DOI":"10.1016\/S0140-6736(02)08782-2"},{"key":"2022061623192193800_B31","doi-asserted-by":"crossref","unstructured":"Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia\u20082003; 17: 700\u20136.","DOI":"10.1038\/sj.leu.2402883"},{"key":"2022061623192193800_B32","doi-asserted-by":"crossref","unstructured":"Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM; Medical Research Council Working Party on Childhood Leukaemia. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol\u20082002; 117: 306\u201314.","DOI":"10.1046\/j.1365-2141.2002.03442.x"},{"key":"2022061623192193800_B33","doi-asserted-by":"crossref","unstructured":"Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood\u20082004; 104: 3527\u201334.","DOI":"10.1182\/blood-2004-04-1390"},{"key":"2022061623192193800_B34","doi-asserted-by":"crossref","unstructured":"Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol\u20082002; 118: 999\u20131010.","DOI":"10.1046\/j.1365-2141.2002.03754.x"},{"key":"2022061623192193800_B35","doi-asserted-by":"crossref","unstructured":"Cave H, van der Werff ten Bosch J, Suciu S, et al.; European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med\u20081998; 339: 591\u20138.","DOI":"10.1056\/NEJM199808273390904"},{"key":"2022061623192193800_B36","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood\u20082000; 96: 2691\u20136.","DOI":"10.1182\/blood.V96.8.2691.h8002691_2691_2696"},{"key":"2022061623192193800_B37","doi-asserted-by":"crossref","unstructured":"Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood\u20081996; 88: 4493\u20139.","DOI":"10.1182\/blood.V88.12.4493.bloodjournal88124493"},{"key":"2022061623192193800_B38","doi-asserted-by":"crossref","unstructured":"Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med\u20082003; 9: 1158\u201365.","DOI":"10.1038\/nm909"},{"key":"2022061623192193800_B39","doi-asserted-by":"crossref","unstructured":"Brown P, Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer\u20082004; 40: 707\u201321.","DOI":"10.1016\/j.ejca.2003.08.030"},{"key":"2022061623192193800_B40","doi-asserted-by":"crossref","unstructured":"Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood\u20082000; 96: 1926\u201332.","DOI":"10.1182\/blood.V96.5.1926"},{"key":"2022061623192193800_B41","doi-asserted-by":"crossref","unstructured":"Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest\u20082007; 117: 1049\u201357.","DOI":"10.1172\/JCI30235"},{"key":"2022061623192193800_B42","doi-asserted-by":"crossref","unstructured":"Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev\u20081995; 9: 1149\u201363.","DOI":"10.1101\/gad.9.10.1149"},{"key":"2022061623192193800_B43","doi-asserted-by":"crossref","unstructured":"Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev\u20081999; 13: 1501\u201312.","DOI":"10.1101\/gad.13.12.1501"},{"key":"2022061623192193800_B44","doi-asserted-by":"crossref","unstructured":"Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science\u20081995; 269: 682\u20135.","DOI":"10.1126\/science.7624798"},{"key":"2022061623192193800_B45","doi-asserted-by":"crossref","unstructured":"Kato Y, Iwama A, Tadokoro Y, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med\u20082005; 202: 169\u201379.","DOI":"10.1084\/jem.20042541"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9852\/2576595\/9852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/20\/9852\/2576595\/9852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:18:06Z","timestamp":1655417886000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/20\/9852\/533833\/Fms-like-Tyrosine-Kinase-3-Ligand-Stimulation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,15]]},"references-count":45,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2007,10,17]]},"published-print":{"date-parts":[[2007,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-0105","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22371218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371218.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496706.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496706","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,15]]}}}